BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, May 5, 2014
At least 25 companies reported earnings last week. Shire
plc (LSE:SHP; NASDAQ:SHPG) was up 7% last week, tacking on $2.3 billion in
market cap. The biopharma reported earnings per ADS that beat the Street's
estimate, thanks in part to a decline in non-GAAP R&D, and raised its 2014
earnings guidance. Also last week, Shire said it will acquire fibrosis play Fibrotech
Therapeutics Pty. Ltd. for $75 million up front (see B5).
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)
gained 3% last week, adding $508 million in market value. The biotech beat the
Street's non-GAAP EPS estimate on lower-than-expected R&D and SG&A
expenses and also reported Phase II data showing that once-daily VX-661 added
to stable Kalydeco ivacaftor reduced sweat chloride and improved lung function
in cystic fibrosis (CF) patients with both the delta F508 CF transmembrane
conductance regulator (CFTR) mutation and G551D CFTR mutation (see B25).
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]